Editorial
Reliability of Ventricular Remodeling as a Surrogate for Use in Conjunction With Clinical Outcomes in Heart Failure

https://doi.org/10.1016/j.amjcard.2005.05.037Get rights and content

As the number of treatments for heart failure (HF) increases and mortality decreases in the setting of clinical trials, the size of the study population required to demonstrate an incremental difference in survival with each new agent may become prohibitive. There has been increasing interest in identifying and validating surrogate end points for assessing HF treatments. The strong association between ventricular remodeling and clinical outcomes supports the incorporation of measures of ventricular volumes into clinical trials of new therapies for HF. A finding of reduced left ventricular volumes renders a particular survival signal more credible. It is therefore appropriate to consider ventricular remodeling in conjunction with outcome events in the construct of clinical trials in HF.

References (46)

  • M.A. Konstam et al.

    Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failureresults of the ELITE ventricular function substudy

    Am Heart J

    (2000)
  • M. Wong et al.

    Valsartan benefits left ventricular structure and function in heart failureVal-HeFT echocardiographic study

    J Am Coll Cardiol

    (2002)
  • A.P. Maggioni et al.

    Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

    J Am Coll Cardiol

    (2002)
  • M. Wong et al.

    Severity of left ventricular remodeling defines outcomes and response to therapy in heart failureValsartan Heart Failure Trial (Val-HeFT) echocardiographic data

    J Am Coll Cardiol

    (2004)
  • S.A. Hall et al.

    Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade

    J Am Coll Cardiol

    (1995)
  • R.N. Doughty et al.

    Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group

    J Am Coll Cardiol

    (1997)
  • T. Tsutamoto et al.

    Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

    J Am Coll Cardiol

    (2001)
  • J.N. Cohn

    Remodeling as an end-point in heart failure therapy

    Cardiovasc Drugs Ther

    (2004)
  • J.N. Cohn et al.

    Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure

    Circulation

    (1993)
  • M. Wong et al.

    Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failureVeterans Affairs cooperative studies V-HeFT I and II

    Circulation

    (1993)
  • R.S. Vasan et al.

    Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction

    N Engl J Med

    (1997)
  • S.A. Hunt et al.

    ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)

    Circulation

    (2001)
  • Cited by (46)

    • Clinical significance of ischemia-like electrocardiographic finding during heart failure treatment on left ventricular recovery in patients with non-ischemic dilated cardiomyopathy

      2021, Journal of Cardiology
      Citation Excerpt :

      LV remodeling is a major pathogenic mechanism in heart failure (HF) progression and a predictor of prognosis [2]. The inverse process, left ventricular reverse remodeling (LVRR), characterized by a reduction in LV volume and an improvement in LV systolic function, is related to favorable long-term prognosis [3], derived either spontaneously [4] or after the introduction of neurohumoral therapy [5,6]. Previous studies showed that various factors such as sex [7], serum markers [8], genetic basis [9], echocardiographic indices [10–12], and late gadolinium enhancement in cardiac magnetic resonance imaging (CMR) [13,14] predicted LVRR in patients with HF.

    • Genetic determinants of responsiveness to mesenchymal stem cell injections in non-ischemic dilated cardiomyopathy

      2019, EBioMedicine
      Citation Excerpt :

      Since a significant proportion of the NIDCM population burden appears to be familial, and are associated with variants in specific genes [2,3], we sought to test the hypothesis that genetic factors predict clinical responses and correlate with patient recovery. Improvement of left ventricle function (LV) and/or restoration of LV geometry, referred to as reverse remodeling, is associated with improved quality of life (QOL) [4], and with reductions in mortality [5], left ventricular assist device (LVAD) implantation, heart transplants, and hospitalization [6]. The therapeutic response of HFrecEF is a recognized outcome with improved prognosis compared to HF with a persistently reduced EF [7].

    • Heart Failure with Myocardial Recovery - The Patient Whose Heart Failure Has Improved: What Next?

      2017, Progress in Cardiovascular Diseases
      Citation Excerpt :

      Also, myocardial recovery is more likely in patients with a shorter duration and less myocardial fibrosis.19,43 Improvement of LVEF has been systematically linked to improved quality of life and lower rehospitalization rates and mortality, regardless of how it is achieved.20 HFrecEF patients have often milder symptoms, with patients mainly functioning in New York Heart Association (NYHA) class I or II.17

    View all citing articles on Scopus

    This study was supported by a grant from Novartis Pharmaceuticals, East Hanover, New Jersey.

    View full text